Pralatrexate

Pralatrexate

CAT N°: 23689
Price:

From 548.00 465.80

Pralatrexate is a dihydrofolate reductase (DHFR) inhibitor (Ki = 13.4 pM) and antifolate.{39422} It inhibits growth of CCRF-CEM acute lymphocytic leukemia cells (IC50 = 0.04 ?M), MDA-468, SK-BR-3, and ZR-75-1 breast cancer cells (IC50s = 0.11, 0.28, and 0.26 ?M, respectively), and SK-LC8 and SK-LC16 non-small cell lung cancer cells (NSCLC; IC50s = 0.42 and 0.11 ?M, respectively). In vivo, pralatrexate increases median survival from 21 to 40 days when administered in 4 doses of 15 mg/kg over 11 days in an H9 T cell lymphoma mouse xenograft model.{39423} Pralatrexate is transported into cells via the reduced folate carrier (RFC) and undergoes polyglutamation by folylpolyglutamate synthetase (FPGS) to a greater extent than methotrexate (Item No. 13960) or pemetrexed (Item No. 14269).{39424,39425} Formulations containing pralatrexate have been used in the treatment of relapsed or refractory peripheral T cell lymphoma.

We also advise you

TAF 10 Peptide

TAF 10 Peptide

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity.{16903} One vial of this peptide...

€191.00
View